A new development bulk drug plant has been opened by Zeneca at thefirm's international manufacturing and development site in Macclesfield, UK. The facility represents a L12 million ($19.7 million) investment, and provides a 2,500 liter process plant containing novel equipment designed to handle complex syntheses, according to the company.
The plant will supplement existing capacity, ensuring rapid progress of new compounds through the development phase, said Zeneca.
Tom McKillop, chief executive of Zeneca Pharmaceuticals, said: "the achievement of accelerated development timescales is critically dependent on having adequate and flexible processing capability. This plant is the most recent and largest of our development bulk drug facilities, which were planned to meet the demands resulting from the increased number of compounds going into clinical trials each year."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze